Terumo BCT has secured a Defense Department contract worth up to $29.9 million to improve its pathogen reduction technologies. Funding will help the company seek FDA approval of its Mirasol system and support testing and clinical trials. Terumo BCT will collaborate with the Army Medical Research and Material Command.

Related Summaries